Philippines and MAINZ, GERMANY, June 22, 2021 — Pfizer Philippines and BioNTech SE today announced an agreement with the Department of Health and the National Task Force Against Covid-19 on behalf of the Government of the Republic of the Philippines to supply 40 million doses of their COVID-19 Vaccine (BNT162b2) through 2021.
Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses.
“We are deeply honored to work with the Government of the Republic of the Philippines and to marshal our scientific and manufacturing resources toward our shared goal of bringing a COVID-19 vaccine to the Filipino people as quickly as possible,” said Edilberto Reyes, Pfizer Philippines Country Manager. “In the face of this global health crisis, Pfizer’s purpose – breakthroughs that change patients’ lives – has taken on an even greater urgency.”
“I would like to thank the Government of the Republic of the Philippines for its support and putting trust in our ability to develop a vaccine that, we believe, has the potential to help address this global pandemic threat. Our goal remains to deliver a global supply of a well-tolerated and effective COVID-19 vaccine for many people around the world, as quickly as we can,” said Sean Marett, Chief Business and Chief Commercial Officer at BioNTech.
Pfizer and BioNTech aim to manufacture approximately 3 billion doses of their COVID-19 vaccine globally by the end of 2021, assuming updated six-dose labeling, continuous process improvements, expansion at current facilities and contingent upon adding new suppliers and contract manufacturers.
The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States (jointly with Pfizer), Canada and other countries in advance of a planned application for full marketing authorizations in these countries.
